专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11447542B2 Anti-O2 antibodies and uses thereof 有权
公开(公告)号：US11447542B2
公开(公告)日：2022-09-20
申请号：US16323185
申请日：2017-08-04
申请人： MEDIMMUNE, LLC , Humabs BioMed SA
发明人： Qun Wang , Charles K. Stover , Meghan Pennini , Xiaodong Xiao , Davide Corti , Elisabetta Cameroni , Martina Beltramello , Gilad Kaplan , Anna DeMarco
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/00 , A61K39/40 , A61K39/108 , C07K16/12 , A61P31/04 , A61K31/407
摘要： The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

2. 发明授权

US11306139B2 Glycosylated immunoglobulin single variable domains 有权
公开(公告)号：US11306139B2
公开(公告)日：2022-04-19
申请号：US15554744
申请日：2016-03-18
申请人： Ablynx N.V.
发明人： Marie-Ange Buyse , Carlo Boutton
IPC分类号： A61K39/00 , C07K16/00 , C12P21/08 , C07K16/18
摘要： The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present. For example, the present invention relates to heavy-chain immunoglobulin variable domain, which contains a glycosylation site such that the amino acid residue at one of positions 10, 11, 12, 13, 14, 39, 40, 41, 42, 87, 89, 108, 110, 112, 113 or 114, and in particular one of positions 11, 13, 87, 89, 108, 110, 112, 113 or 114 (numbering according to Kabat) is or can be glycosylated.

3. 发明授权

US11286300B2 Humanized anti-human CD19 antibodies and methods of use 有权
公开(公告)号：US11286300B2
公开(公告)日：2022-03-29
申请号：US15763868
申请日：2016-09-30
申请人： Hoffmann-La Roche Inc.
发明人： Claudia Ferrara Koller , Guy Georges , Alexander Haas , Hubert Kettenberger , Ekkehard Moessner , Tilman Schlothauer , Michael Molhoj , Laurent Lariviere
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/40 , C07K16/28 , C07K1/00
摘要： Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

4. 发明授权

US11248043B2 Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof 有权
公开(公告)号：US11248043B2
公开(公告)日：2022-02-15
申请号：US16919032
申请日：2020-07-01
申请人： AMGEN INC.
发明人： Neeraj Jagdish Agrawal , Kevin Graham , Agnes Eva Hamburger , Christopher Mohr , Derek E. Piper , Kenneth William Walker , Zhulun Wang , Cen Xu
IPC分类号： G01N33/53 , A61K39/395 , A61K39/00 , A61K49/00 , A61K49/16 , C07K16/00 , C12P21/08 , C07K16/18 , C07K16/28 , A61P25/06 , A61K38/22 , A61K47/68 , A61K38/17 , A61K51/10 , C07K14/575 , C07K16/26 , C07K14/72 , C07K14/47 , G01N33/74 , G01N33/68
摘要： The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

5. 发明授权

US11098125B2 FcγRIIB-specific antibodies and methods of use thereof 有权
公开(公告)号：US11098125B2
公开(公告)日：2021-08-24
申请号：US16123816
申请日：2018-09-06
申请人： MacroGenics, Inc.
发明人： Leslie S. Johnson , Ling Huang , Robyn Gerena
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , C07K16/28 , A61K45/06 , C07K1/00 , A61K39/00
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

6. 发明授权

US11067583B2 Methods of making active antibodies from biological fluids 有权
公开(公告)号：US11067583B2
公开(公告)日：2021-07-20
申请号：US16302525
申请日：2017-05-25
申请人： University of Maryland, Baltimore , The United States of America as represented by the Department of Veterans Affairs
发明人： Mohammad Sajadi , Anthony DeVico , George Lewis
IPC分类号： C07K16/00 , C07H21/04 , C12P21/08 , A61K39/395 , C07K1/00 , G01N33/68 , C07K1/22 , C07K16/10 , H01J49/26
摘要： The present invention provides a method of making an antibody by identifying a circulating antibody with activity from a subject comprising i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody; ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge; iii) testing the purified circulating antibody for activity; iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment; v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence; vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deducted amino acid sequence of party vi); and viii) testing the antibody of part vii) for activity.

7. 发明授权

US10981984B2 Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion 有权
公开(公告)号：US10981984B2
公开(公告)日：2021-04-20
申请号：US16217567
申请日：2018-12-12
申请人： ALDER BIOPHARMACEUTICALS, INC. , The University of Iowa Research Foundation
发明人： Adisa Kuburas , Bianca Mason , Levi P. Sowers , Andrew F. Russo , Maria-Cristina Loomis , Leon F. Garcia-Martinez , Benjamin H. Dutzar , Daniel S. Allison , Katherine Lee Hendricks , Ethan W. Ojala , Pei Fan , Jeffrey T. L. Smith , John A. Latham , Charlie Karasek , Jenny Mulligan , Michelle Scalley-Kim , Erica Stewart , Vanessa Lisbeth Rubin , Jens J. Billgren
IPC分类号： A61K49/00 , A61K49/16 , A61K39/395 , A61K39/00 , G01N33/53 , C07K16/00 , C12P21/08 , C07K16/26 , A61P25/06 , G01N33/50 , A61K45/06 , G01N33/74 , C07K16/42 , C07K14/575
摘要： This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

8. 发明授权

US10968277B2 Gene signatures for determining ICOS expression 有权
公开(公告)号：US10968277B2
公开(公告)日：2021-04-06
申请号：US15767172
申请日：2016-10-21
申请人： Jounce Therapeutics, Inc.
发明人： Jason Windham Reeves , Igor Feldman , Christopher Harvey , Sriram Sathyanarayanan , Heather Hirsch , Lauren Pepper MacKenzie , Amit Deshpande , Stephen Sazinsky , Jennifer S. Michaelson , Kutlu Goksu Elpek
IPC分类号： C07K16/00 , C12P21/08 , A61P35/00 , C07K16/28 , C12Q1/6886 , A61K39/00 , A61K39/395
摘要： Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

9. 发明授权

US10954293B2 Correctly folded etanercept in high purity and excellent yield 有权
公开(公告)号：US10954293B2
公开(公告)日：2021-03-23
申请号：US16443514
申请日：2019-06-17
申请人： COHERUS BIOSCIENCES, INC.
发明人： Tsutomu Arakawa , Douglas Farrar
IPC分类号： A61K39/00 , C07K16/00 , C12P21/08 , C07K16/24 , C07K14/705 , C07K1/16 , A61K39/395
摘要： A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided. The method is highly effective in separating correctly folded etanercept from incorrectly folded etanercept and aggregates in commercially attractive yields capable of affording etanercept preparations having very high purity in terms of correctly folded etanercept versus incorrectly folded etanercept. The invention is further directed to protein preparations and formulations comprising correctly folded proteins obtained using the present methods, and methods of treatment using the high purity preparations obtained from the mixed mode method.

10. 发明授权

US10919953B2 FcgammaRIIB-specific Fc region variant 有权
公开(公告)号：US10919953B2
公开(公告)日：2021-02-16
申请号：US14423269
申请日：2013-08-23
申请人： Chugai Seiyaku Kabushiki Kaisha
发明人： Hitoshi Katada , Shojiro Kadono , Futa Mimoto , Tomoyuki Igawa
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , C07K16/30 , C07K16/28 , C07K1/00 , A61K9/00 , A61K39/00
摘要： An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R).
It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances FcγRIIb-binding activity, and/or enhances binding selectivity to FcγRIIb compared to FcγRIIa (type R).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式